Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.40 |
| ▸ | PPARD | Q03181 | 6/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4085279 | 0.81 | HSD17B1 (0.45) | HSD17B1CYP11B1CYP11B2 | |
| SCHEMBL4093483 | 0.77 | HSD17B1 (0.50) | HSD17B1 | |
| SCHEMBL19158973 | 0.75 | ERN1 (0.53) | ERN1FFAR1PPARDMRGPRX4CTSA | |
| SCHEMBL7737589 | 0.73 | METAP1 (0.52) | — | |
| SCHEMBL8993210 | 0.71 | ERN1 (0.56) | ERN1S1PR5FFAR1PPARDMRGPRX4 | |
| SCHEMBL27536787 | 0.71 | S1PR5 (0.53) | S1PR5FFAR1PPARDPPARGMRGPRX4 | |
| SCHEMBL9854934 | 0.70 | METAP1 (0.60) | PPARG | |
| SCHEMBL13424043 | 0.69 | FFAR1 (0.51) | S1PR5FFAR1PPARDPPARG | |
| SCHEMBL14513314 | 0.68 | ERN1 (0.54) | ERN1S1PR5FFAR1PPARDMRGPRX4 | |
| SCHEMBL10093047 | 0.68 | ERN1 (0.55) | ERN1S1PR5FFAR1PPARDMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| EP-2013176-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | Sterix Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186900-A1 | COMPOUND | HSD17B2, HSD17B11, CYP17A1 | ERN1 2125/4885S1PR5 2779/4885HSD17B1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.